{"id":"W2775300375","doi":"10.1016/j.ejca.2017.11.004","title":"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Veliparib; Medicine; Internal medicine; Gastroenterology; Clinical endpoint; Hazard ratio; PARP inhibitor; Oncology; BRCA mutation; Phases of clinical research; Pancreatic cancer; Confidence interval; Surgery; Cancer; Clinical trial; Breast cancer; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009014331,0.001205563,0.00196084,0.0002896951,0.0004039403,0.001293807,0.0008101418,0.001092716,0.003248557],"category_scores_gemma":[0.0009377898,0.0005157541,0.001329278,0.000347976,0.000938779,0.0009788731,0.0003937809,0.003165269,0.0008517911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009373011,"about_ca_system_score_gemma":0.001043271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006889172,"about_ca_topic_score_gemma":0.001681351,"domain_scores_codex":[0.9997565,0.0001033105,0.000009875111,0.00005159071,0.00001512063,0.00006352244],"domain_scores_gemma":[0.9995491,0.0001053732,0.00006785226,0.00004045192,0.00001692682,0.0002203318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7515934,0.02481852,0.00683063,0.001181576,0.002344242,0.0006826957,0.0003551123,0.009242238,0.03206781,0.001033362,0.008896206,0.1609542],"study_design_scores_gemma":[0.7719896,0.203166,0.008652537,0.0001016185,0.0006829088,0.0008649258,0.0001548557,0.003892858,0.003262212,0.001078805,0.006101229,0.00005235886],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896023,0.003542752,0.0006784984,0.00100405,0.0002372974,0.0008414883,0.0009395715,0.0001477287,0.003006355],"genre_scores_gemma":[0.9899638,0.00232215,0.001017174,0.000915692,0.0001494728,0.0008699721,0.001837958,0.00003978131,0.002884014],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003248557,"threshold_uncertainty_score":0.01086748,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03449127913236837,"score_gpt":0.3551758726349117,"score_spread":0.3206845935025433,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}